Clinical Trials Browser

Phase 2 × INDUSTRY × Epoetin Alfa × Clear all

NCT00267007 2014-06-04

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

Phase 2 Terminated

32 enrolled 9 charts

Neoplasms, Peripheral Nervous System Diseases

NCT00386152 2013-07-19

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Phase 2 Terminated

235 enrolled 13 charts

Classical hematology

Anemia, Neoplasms

NCT00210600 2011-06-10

Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy

Phase 2 Completed

Classical hematology

Anemia

NCT00210834 2011-06-10

An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.

Phase 2 Completed

Classical hematology

Anemia

NCT00337948 2011-06-10

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks

Phase 2 Completed

Classical hematology

Anemia, Neoplasms

NCT00338416 2011-06-10

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

Phase 2 Completed

Classical hematology

Anemia, Neoplasms

NCT00269984 2011-06-08

A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer

Phase 2 Completed

Classical hematology

Anemia, Neoplasms

NCT00338299 2011-05-23

Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia

Phase 2 Completed

Classical hematology

Anemia

NCT00266617 2011-05-18

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy

Phase 2 Completed

Classical hematology

Anemia, Neoplasms

NCT00269997 2011-05-18

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug

Phase 2 Completed

Classical hematology

Anemia, Neoplasms

NCT00270049 2011-05-18

Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia

Phase 2 Completed

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Leukemia, Lymphoid, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00388336 2011-05-18

PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy

Phase 2 Completed

Classical hematology

Anemia, Neoplasms